Cyclic Cushing's syndrome (also known as intermittent or periodic) is a disease
characterized by periods of transient hypercortisolemia shifting into periods of normo-and/or …

The ongoing coronavirus disease 2019 (COVID-19) pandemic forced a change in the way
we provide medical treatment. Endocrinology in the era of COVID-19 had to transform and …

Aggressive pituitary neuroendocrine tumors (APT) account for 10% of pituitary tumors. Their
management is a rapidly evolving field of clinical research and has led pituitary teams to …

Management of aggressive pituitary adenomas is challenging due to a paucity of rigorous
evidence supporting available treatment approaches. Recent guidelines emphasize the …

Nonfunctioning pituitary neuroendocrine tumors (NF-PitNETs) are tumors that are not
associated with clinical evidence of hormonal hypersecretion. According to the World Health …

Epigenetic modification of chromatin is involved in non-malignant pituitary neoplasia by
causing abnormal expression of tumor suppressors and oncogenes. These changes are …

Context Precision medicine for pituitary neuroendocrine tumors (PitNETs) is limited by the
lack of reliable research models. Objective To generate patient-derived organoids (PDOs) …

Purpose Somatotroph adenomas are obviously heterogeneous in clinical characteristics,
imaging performance, pathological diagnosis and therapeutic effect. The heterogeneity of …

Aggressive pituitary corticotroph tumors causing Cushing's disease are rare, and there is
limited data about their clinical management. Here, we aimed to report our long-term …

The rare aggressive pituitary adenoma presents a special challenge, due to the
heterogenous presentation of the disease. The prognosis of aggressive pituitary adenomas …